FOXP3 and Alzheimer disease: Our study identifies systemic Foxp3+ Treg-mediated immunosuppression as a negative player in AD pathology, acting at least in part by reducing CP IFN-γ availability needed for gateway activity of this compartment in orchestrating recruitment of leukocytes to the CNS (refs 17, 18, 19, 25).